Diamyd Medical AB Reports Third Quarter Financial Results
Stockholm, June 25, 2025 — Diamyd Medical AB, a biotechnology company specializing in autoimmune diabetes treatments, has released its financial results for the third quarter of the fiscal year 2024/2025. The company, listed on the Swedish Stock Exchange, reported a decrease in its operating result, with no revenue generated during this period.
Financial Overview
For the third quarter, Diamyd Medical AB reported an operating loss of SEK -48.1 million, a deterioration from the previous year’s loss of SEK -42.3 million. The company’s revenue remained at SEK 0.0 million, consistent with the previous quarter’s figures. This financial performance reflects the ongoing challenges faced by the company in its research and development efforts.
Market Reaction
The company’s stock price closed at SEK 8.88 on May 29, 2025, down from a 52-week high of SEK 25 on July 30, 2024, and above a 52-week low of SEK 7.5 on April 21, 2025. The market capitalization stands at SEK 1,270,000,000. The price-to-earnings ratio is currently at -5.6, indicating the company’s ongoing financial challenges.
Company Focus
Diamyd Medical AB continues to focus on the development of its key products, Diamyd and Remygen. Diamyd is a Phase IIb clinical trial diabetes vaccine, while Remygen is a regenerative and immunomodulatory therapy in phases Ib/IIa for autoimmune and type 2 diabetes treatment. The company’s CEO has expressed optimism about the recruitment for the Diagnode-3 trial, expecting it to be completed within the year.
Market Context
On the broader market front, the OMXS30 index saw a slight increase of 0.3% in early trading on the same day, influenced by various factors including the NATO summit in The Hague. Analysts anticipate minimal changes in the early Wednesday trading session.
Diamyd Medical AB remains committed to advancing its research and development efforts, despite the financial setbacks reported in the third quarter. The company continues to navigate the complexities of the biotechnology sector, with a focus on delivering innovative treatments for autoimmune diabetes.